REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 41
- Part 41: For the preceding part double click ID:nRSH4027RN
renminbi, Australian dollar and Canadian dollar. We have a growing
exposure to Emerging Market currencies, some of which are subject to
exchange controls, and these currencies, such as that of Venezuela, may
be subject to material devaluations against the US dollar. Major
components of our cost base are located in the UK and Sweden, where an
aggregate of approximately 20% of our employees are based. Limited third
party insurance coverageIn recent years, the costs associated with
product liability litigation have increased the cost of, and narrowed the
coverage afforded by, pharmaceutical companies' product liability
insurance. To contain insurance costs in recent years, we have continued
to adjust our coverage profile, accepting a greater degree of uninsured
exposure. The Group has not held any material product liability insurance
- More to follow, for following part double click ID:nRSH4027RPRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement